DEFENCATH ?:Hemodialysis Center Venous Catheter Lock Solution
10.3870/j.issn.1004-0781.2024.09.017
- VernacularTitle:血液透析中心静脉导管封管液——DEFENCATH?
- Author:
Hongmiao LIU
1
;
Zhonghua ZHAO
;
Huan LIU
;
Fangliang ZHAO
;
Yanling LI
Author Information
1. 河北医科大学第一医院药剂科,石家庄 050031
- Keywords:
DEFENCATH?;
Taurolidine/Heparin;
Catheter-related blood stream infeation;
Catheter lock solution;
Hemodialysis
- From:
Herald of Medicine
2024;43(9):1457-1460
- CountryChina
- Language:Chinese
-
Abstract:
DEFENCATH?(taurolidine/heparin)is the first hemodialysis central venous catheter lock solution approved by the FDA.Taurolidine has broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacterium and fungal species and anti-endotoxin and anti-exotoxin activities.Moreover,microbial resistance has not been observed,and the safety is good.Low-dose heparin is effective in anticoagulation and has a low risk of bleeding,and the two complement each other,clinical studies have reported that the catheter lock solution(CLS)effectively reduces the incidence of catheter-related blood stream infection(CRBSI),with good safety and significant clinical value.It will bring benefits to renal failure patients undergoing maintenance hemodialysis.
